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Background
We compared the outcomes of patients with Burkitt lymphoma and French-American- 
British (FAB) L3 acute lymphoblastic leukemia treated using Lymphoma Malignancy B 
(LMB) or other treatment protocols.
Methods
Thirty-eight patients diagnosed between July 1996 and December 2007 were treated us-
ing LMB 96, and 22 patients diagnosed between January 1991 and May 1998 (defined 
as the early period) were treated using the D-COMP or CCG-106B protocols. We retro-
spectively reviewed their medical records and analyzed cumulative survival according 
to the treatment period by using Kaplan-Meier analysis.
Results
There were no intergroup differences in the distribution of age, disease stage, or risk group. 
The median follow-up period of the 33 live patients in the LMB group was 72 months 
(range, 36-170 months). Overall survival (OS) and event-free survival (EFS) of patients 
treated using LMB 96 were 86.8%±5.5% and 81.6%±6.3%, respectively, whereas OS and 
EFS of patients treated in the early period were 72.7%±9.6% and 68.2%±9.9%,
respectively. In the LMB 96 group, OS of cases showing non-complete response (N=8) 
was 62.5%±17.1%, and OS of relapsed or primary refractory cases (N=6) was 33.3%±
19.3%. Central nervous system (CNS) disease, high lactate dehydrogenase levels at diag-
nosis, and treatment response were significant prognostic factors.
Conclusion
Survival outcome has drastically improved over the last 2 decades with short-term, 
dose-intensive chemotherapy. However, CNS involvement or poor response to chemo-
therapy was worse prognostic factors; therefore, future studies addressing this ther-
apeutic challenge are warranted.
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INTRODUCTION
Burkitt lymphoma (BL) originates from B lymphocytes 
that have characteristic surface immunoglobulin markers due 
to translocation of the myc gene [1, 2]. French-American- 
British (FAB) L3 acute lymphoblastic leukemia (L3 ALL) 
is considered to be in the same disease category. BL is well- 
known to have a rapid growth rate. It frequently spreads 
systemically prior to the time of diagnosis; thus, 70% to 
80% of patients are in the advanced stages of disease. In 
addition, early death due to tumor lysis syndrome is frequent, 
owing to the high turnover rate of these tumor cells. 
However, survival outcome has drastically improved over 
the last 2 decades following the Lymphoma Malignancy B 
(LMB) study by the French Society of Pediatric Oncology Korean J Hematol 2011;46:96-102.
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Fig. 1. LMB 96 protocol schedule 
[8]. Patients were stratified into 3 
risk groups: A, B, and C, depending 
on stage, resection status, percen-
tage of blasts in BM, and CNS in-
volvement. Group A: Resected stage
I and abdominal stage II. Group B: 
Patients not eligible for inclusion in 
group A or C. Group C: Patient with 
CNS involvement and more than 
70% of blast in bone marrow. In the 
LMB 96 protocol, cranial irradiation 
was skipped and replaced with 
high-dose methotrexate (MTX) be-
tween consolidation phases in pa-
tients with CNS-positive disease.
(SFOP). In the LMB 81 study, 9 drugs were used for 1 year, 
but acute toxic death was still an area of concern [3]. A 
subsequent study, LMB 84, concluded that poor responders 
(tumor response ＜20% at day 7) have a poor outcome [4]. 
Even in patients with central nervous system (CNS) involve-
ment, which is known to result in a poorer survival outcome, 
event-free survival (EFS) of over 70% could be achieved 
by dose escalation of methotrexate (8 g/m
2) and addition 
of cytarabine (cytosine arabinoside; Ara-C) and etoposide 
(VP-16) [5, 6].
In our institution, the D-COMP or CCG-106B protocols 
were used earlier, but since the late 1990s, the LMB protocol 
has been uniformly applied for the treatment of BL. The 
authors previously reported preliminary data on the treat-
ment outcomes and toxicity in 10 patients treated using 
LMB 96 [7]. In this report, we aimed to analyze differences 
in the survival outcomes of patients treated using LMB 96 
[8] and using D-COMP [9] or CCG-106B [10].
MATERIALS AND METHODS
1. Patients 
　Forty patients treated with the LMB 96 protocol from 
July 1996 to December 2007 (LMB group), and 26 patients 
treated with D-COMP (stage I-III) [9] or CCG-106B (stage 
IV) [10] from January 1990 to June 1998 (early-period group) 
were enrolled. Two patients who were lost to follow-up 
in the LMB group and 4 in the early group (3 discharged 
themselves against medical advice and the medical records 
of 1 were lost) were excluded from this analysis. This study 
was approved by the institutional review board. 
2. Treatment and response criteria
The primary tumor site(s), lactate dehydrogenase (LDH) 
levels, and stage were investigated. The primary site(s) were 
categorized as follows: head and neck, abdomen, chest, pe-
ripheral lymph node, etc. The staging study included evalua-
tion of peripheral blood and bone marrow (BM) aspirate 
smears, cerebrospinal fluid (CSF) analysis, radiography, ultra-
sonography, computed tomography (CT) or magnetic reso-
nance imaging (MRI), and skeletal scintigraphy. BL was diag-
nosed on the basis of morphological and immunohistoche-
mical characteristics. A mature B-cell immunophenotype 
was defined by reactivity of B-cell antigens (CD10, CD19, 
CD20 in cell suspension or CD20, CD79a, BCL2 in fixed 
tissue) and monoclonality of surface immunoglobulins. 
Chromosomal translocations such as t(8;14), t(8;22), and 
t(2;8) were evaluated by karyotyping analysis. A diagnosis 
of L3 ALL was made when blasts had infiltrated more than 
25% of the BM aspirates. CNS disease was diagnosed in 
cases with CSF containing more than 5 cells/μL and showing 
morphologically identifiable blasts on cytospin preparations, 
and in the presence of cerebral infiltrates on cranial CT 
or MRI scans. The Murphy staging system was used [11]. 
Risk groups were stratified into classes A, B, or C according 
to the definition of the LMB group (Fig. 1) [8]. Patients 
diagnosed between 1990 and 1998 were treated using D- 
COMP or CCG-106B, and patients diagnosed between 1996 
and 2007 were treated using the LMB 96 protocol. Complete 
response (CR) was defined as no evidence of residual disease. 
Partial response (PR) was defined as at least 50% reduction 
in tumor burden from the onset of treatment. Progressive 
disease (PD) was defined as at least 25% increase in the 
size of lesions. 
3. Statistical analysis
Differences in the distribution of individual parameters 
among patient subsets were analyzed using the chi-square 
test or Student’s t test. Overall survival (OS) was calculated 
from the date of diagnosis to the last follow-up. EFS was 
calculated from the date of diagnosis to the first event (death 
from any cause, tumor relapse, or progression) or to the 
date of last follow-up. The cut-off date for data analysis 
was December 2010. Analysis of OS and EFS was performed 
using the Kaplan-Meier method, with the differences com-Korean J Hematol 2011;46:96-102.
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Table 1. Demographic and disease characteristics.
Early period LMB 96
P
(1990.1-1998.5) (1996.6-2007.12) 
N 22  38
Male, No. (%)  22 (100) 32 (82)  0.03
Mean age, years  8.2 (3.5-14.6)  7 (0.8-15.1)  1.0
 (range)
　No. ≥10-15 years  5  10 
Pathologic diagnosis 
　Burkitt 21 31  0.07
　Mature B-ALL 1  7 
Primary site  0.41 
　Head and neck  10  19 
　Abdomen 10 10 
　Thorax 1 4 
　Peripheral LN  1  2 
　Not specified  -  3 
BM involvement      0.19 
　＜25% 4 10
　≥25% 1  7 
Stage 0.19 
　I6  3  
　II 2 7
　III 4 6 
　IV 10 22
LMB grouping  0.10 
　A 6  2 
　B 9  21 
　C CNS
-ve 0  7 
　CNS
+ve 7  8 
Fig. 2. Outcome in patients treated 
using the LMB protocol. Three 
patients showed relapse (RL) after 
complete response (CR), and 2 of 
them responded to salvage therapy 
and are alive with no evidence of 
disease. Cases that did not show CR 
after the first consolidation chemo-
therapy included 5 cases of partial 
response (PR) and 3 refractory (ref) 
cases. One case of toxic death 
occurred during induction chemo-
therapy. 
pared using the log-rank test [12]. Statistical analysis was 
carried out using the SPSS statistical program (version 13). 
P-values less than 0.05 were considered statistically signi-
ficant.
RESULTS
1. Primary site and stage of disease
Median age at diagnosis in the LMB group was 7 years 
(range, 0.8-15.1 years), and 10 patients (26.3%) were over 
10 years old. The most common primary sites, in descending 
order of frequency, were the head and neck (50%), abdomen 
(26.3%), chest (10.5%), and peripheral lymph node (5.3%). 
Twenty-eight of the 38 patients (78.3%) were diagnosed 
with stage III or IV disease, including 7 L3 ALL (18.4%) 
and 8 CNS-positive (21.1%) cases. In the LMB group, 2 pa-
tients were in risk group A, 21 in B (55%), and 15 in C 
(39%). Group B had a heterogeneous distribution of stages: 
stage I, 2 patients; stage II, 6 patients; stage III, 6 patients; 
and stage IV, 7 patients. Differences in the demographic 
data, primary site(s), and stage distribution between the LMB 
and early-period group are summarized in Table 1. There 
were no differences in the distribution of age, disease stage, 
or risk group between the 2 groups.
2. Initial LDH levels 
LDH levels of 22 of the 38 patients in the LMB group 
were analyzed. Fifteen patients (62.5%) had 2-fold elevated 
LDH levels, and the mean LDH level of these patients was 
1,071.1±1,435.3 U/L (range, 178-6,336 U/L), whereas in the 
early-period group, the corresponding value was 834.4±613.8 
U/L (range, 130-2,113 U/L). This difference between the 
2 groups was statistically significant (P＜0.01).
3. Treatment duration
The mean treatment duration was 6.7 months (range, Korean J Hematol 2011;46:96-102.
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Fig. 3. Survival outcome of patients treated using LMB 89 (1996-2007) (A), and according to protocols used in the early period (1990-1998) (B).
Fig. 4. Event-free survival according to stage (A), treatment risk group 
(B), and LDH levels (C).
0.8-10.6 months) for the LMB group and 20.6 months (range, 
17.6-38.3 months) for the early-period group (P＜0.01).
4. Treatment response and outcomes
Treatment outcomes in patients treated with LMB 96 are 
shown in Fig. 2. Of 38 patients, 8 (21%) had not reached Korean J Hematol 2011;46:96-102.
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Fig. 5. Comparative analysis of event-free survival (EFS) according to the involvement of bone marrow. EFS of patients treated using the LMB protocol
(A) and D-COMP or 106B protocols (B). In the early period, differences in EFS between groups with or without bone marrow involvement were 
significant (P=0.01). However, the differences between these groups were not significant in patients treated using the LMB protocol. 
Fig. 6. Comparative analysis of event-free survival (EFS) according to the involvement of the central nervous system (CNS). EFS of patients treated 
using the LMB protocol (A) and D-COMP or 106B protocols (B). In either treatment group, there was no significant difference in EFS between groups
with or without CNS involvement.
CR when evaluated after their 1
st consolidation chemo-
therapy. Five of them were reassigned to risk group C, and 
after continuous consolidation with Ara-C and VP-16, they 
showed disease-free survival. One patient who was reas-
signed to risk group C had residual lesions at the end of 
chemotherapy and thus received high-dose chemotherapy 
(HDC) with ACNU, cyclophosphamide, and etoposide, fol-
lowed by autologous stem cell transplantation (ASCT), and 
survived disease-free. However, 3 patients with primary re-
fractory disease eventually died of the disease.
Treatment-related mortality occurred in 1 patient with 
bowel involvement (risk group B) during her 1
st induction 
chemotherapy. She suffered from bowel perforation in the 
neutropenic period and died of sepsis.
Three patients showed relapses at 3.7, 6.9, and 6.5 months 
after diagnosis; one of them had a cerebral mass at diagnosis. 
All 3 received retrieval chemotherapy following the CCG- 
106B protocol. Two patients who responded to chemotherapy 
were administered continuous HDC/ASCT 8 and 10 months 
after relapse, but 1 patient who showed no response to salvage 
chemotherapy had PD and eventually died of the disease.
5. Survival analysis
　The median follow-up time of the 33 live patients in the 
LMB group was 72 months (range, 36-170 months); 5-year 
OS and EFS were 86.8±5.5% and 81.6±6.3%, respectively. 
The OS and EFS of patients in the early-period group were 
72.7±9.6% and 68.2±9.9%, respectively. Although there was Korean J Hematol 2011;46:96-102.
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no significant difference in either OS (P=0.15) or EFS (P= 
0.22) between the early and LMB groups, patients in these 
groups showed a tendency of improved survival (Fig. 3). 
EFS according to the disease stage is shown in Fig. 4A. The 
EFS of patients with stage IV disease treated using the LMB 
96 protocol (81.8±8.2%) was significantly higher than that 
of patients treated using D-COMP or CCG-106B (40±15.5%). 
Survival outcomes according to the LMB risk groups are 
shown in Fig. 4B. The EFS of patients with LDH levels 
≥2-fold was 47.6±10.9%, which was significantly lower than 
that of patients with LDH ＜2-fold (P=0.01) (Fig. 4C).
　There was no difference in survival outcome with respect 
to the involvement of BM in the LMB group, whereas the 
EFS of early-period patients with BM involvement was less 
than 25±21.7%. This indicates that BM involvement is no 
longer a poor prognostic factor (Fig. 5). However, the EFS 
of patients with CNS involvement, another known poor prog-
nostic marker, showed no difference between the 2 groups 
(LMB group, 62.5±17.1%; early-period group, 57.1±18.7%, 
P=0.81) (Fig. 6).
In the LMB group, EFS rates of non-CR patients (62.5± 
17.1%) were significantly different from those of CR patients 
(89.7±5.7%; P=0.03), and OS of relapsed or primary refrac-
tory cases (N=6) was 33.3±19.3%.
DISCUSSION
Treatment outcomes of BL have drastically improved over 
the past 25 years following the work of international coopera-
tive study groups, including SFOP. Therefore, we aimed 
to analyze the survival outcome of patients treated using 
the LMB 96 protocol from 1996 to 2007 in a single institution, 
and compare these findings with the outcome of patients 
treated using other induction protocols from 1990 to 1998 
at the same institution. As described above, OS of the LMB 
group in our study was 86.8%, which is a great improvement 
from that of the early-period group (68.2%); this outcome 
was also similar to that of the LMB 89-treated patients of 
SFOP [8].
　A t  d i a g n o s i s ,  r i s k  g r o u p s  w e r e  s t r a t i f i e d  a s  A ,  B ,  o r  C  
according to the tumor stage and resectability in the LMB 
study group, and treatment intensity was adjusted according 
to the risk group. The next assessment was a step-up strategy 
based on the treatment response after initial prephase chemo-
therapy and the first consolidation chemotherapy. Patients 
who did not achieve an adequate response (tumor response 
less than 20%) subsequently received group C chemotherapy. 
Patte et al. [8] reported that 14 of 21 patients who did 
not show an adequate response after prephase chemotherapy 
were reallocated to group C, and EFS of group B was therefore 
improved up to 92%. Unfortunately, we did not evaluate 
tumor response immediately after prephase chemotherapy, 
and thus, therapeutic intervention was not made according 
to chemotherapy response at this point. However, 5 patients 
with PR after the first consolidation chemotherapy were 
reassigned to risk group C, and were administered continued 
consolidation and maintenance chemotherapy; all the 5 pa-
tients are alive without disease. Because more than 55% 
of patients (21/38) at various stages (I-IV) were included 
in group B, risk group reassignment according to drug re-
sponse could help improve the survival of this heterogeneous 
group.
We confirmed that survival of patients with BM involve-
ment drastically improved, and therefore, BM involvement 
is no longer a poor prognostic factor. However, the EFS 
of patients with CNS involvement treated with the LMB 
protocol was not significantly different from that of patients 
with CNS involvement in historical controls. CNS involve-
ment and high LDH levels at diagnosis were confirmed to 
be poor prognostic factors in this study.
　There were 8 non-CR cases and 3 relapsed cases in our 
cohort. Patients with PR and those who underwent salvage 
chemotherapy after relapse were all alive, but all patients 
with primary refractory BL or those who showed no response 
to salvage chemotherapy succumbed to the disease. In partic-
ular, 1 patient with PR and 2 patients who responded to 
retrieval chemotherapy underwent HDC/ASCT. Overall, EFS 
of non-CR patients (21%) was 62.5±17.1%. Previously, re-
lapsed or refractory BL has been reported to have a very 
poor outcome despite treatment with HDC/ASCT [13-16] 
or CD-20 monoclonal antibody [17, 18]. Therefore, innova-
tive treatment modalities using new drugs or prognostic fac-
tors discovered through cancer cell biology research are war-
ranted for this small proportion of patients. 
　Treatment-related acute and late complications are no less 
important than treatment outcome in pediatric oncology. 
We previously reported preliminary data on acute complica-
tions during treatment with the LMB protocol. Neutropenia 
with fever and uncontrolled severe infection were complica-
tions in 87% and 27% of the patients, respectively. Stomatitis 
caused by toxicity greater than grade II was observed in 
39% of the patients [7], and these data are comparable to 
those of the original LMB 89 study (neutropenia with fever, 
85%; RBC transfusion, 71%; and stomatitis, 33% after 
COPADM8 chemotherapy) [8]. Second malignancy and 
long-lasting organ toxicities are also unacceptable side effects. 
A randomized international FAB/LMB 96 trial for dose-re-
ducing treatment of early responding patients (tumor re-
sponse > 20% at day 7) showed that dose-reducing treatment 
was possible without jeopardizing survival. A 4-course treat-
ment, including a total dose of 3.3g/m
2 cyclophosphamide 
and 120-mg/m
2 doxorubicin, has been reported to help pa-
tients in achieving 90% cure rate for early responding patients 
[19]. However, long-term follow-up is required for thorough 
evaluation of infertility, cardiotoxicity, and second malig-
nancy.
Short-term intensive multi-agent chemotherapy was effec-
tive in treating 90% of BL and L3 ALL patients, but about 
40% of patients with CNS involvement were not cured by 
this regimen. Relapsed patients or those with primary re-
fractory disease also had very poor outcomes; thus, we should 
make efforts to identify new prognostic markers correlating 
with drug response or survival outcome, and to find new Korean J Hematol 2011;46:96-102.
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drugs that can be used effectively in first-line or salvage 
therapy for relapsed or primary refractory patients.
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